Health Care [ 8/12 ] | Life Sciences Tools & Services [ 72/75 ]
NYSE | Common Stock
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally.
It operates through two segments, Life Science and Clinical Diagnostics.
The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications.
This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories.
Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software.
The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers.
Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 12, 26 | 2.51 Decreased by -13.45% | 2.71 Decreased by -7.38% |
| Oct 30, 25 | 2.26 Increased by +12.44% | 1.94 Increased by +16.49% |
| Jul 31, 25 | 2.61 Decreased by -16.08% | 1.75 Increased by +49.14% |
| May 1, 25 | 2.54 Increased by +10.92% | 1.78 Increased by +42.70% |
| Feb 13, 25 | 2.90 Decreased by -6.45% | 2.88 Increased by +0.69% |
| Oct 30, 24 | 2.01 Decreased by -13.73% | 1.18 Increased by +70.34% |
| Aug 1, 24 | 3.11 Increased by +3.67% | 2.01 Increased by +54.73% |
| May 7, 24 | 2.29 Decreased by -31.44% | 2.15 Increased by +6.51% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 693.20 M Increased by +3.85% | 720.00 M Increased by +200.59% | Increased by +103.87% Increased by +196.85% |
| Sep 30, 25 | 653.00 M Increased by +0.50% | -341.90 M Decreased by -152.34% | Decreased by -52.36% Decreased by -152.08% |
| Jun 30, 25 | 651.60 M Increased by +2.06% | 317.80 M Increased by +114.68% | Increased by +48.77% Increased by +114.38% |
| Mar 31, 25 | 585.40 M Decreased by -4.16% | 64.00 M Decreased by -83.33% | Increased by +10.93% Decreased by -82.61% |
| Dec 31, 24 | 667.48 M Decreased by -2.01% | -715.80 M Decreased by -304.69% | Decreased by -107.24% Decreased by -308.89% |
| Sep 30, 24 | 649.73 M Increased by +2.79% | 653.17 M Increased by +514.71% | Increased by +100.53% Increased by +498.05% |
| Jun 30, 24 | 638.48 M Decreased by -6.26% | -2.17 B Decreased by -86.32% | Decreased by -339.16% Decreased by -98.76% |
| Mar 31, 24 | 610.82 M Decreased by -9.75% | 383.92 M Increased by +456.71% | Increased by +62.85% Increased by +516.88% |